Robert J Slack

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4489378/publications.pdf

Version: 2024-02-01

1306789 1473754 9 338 7 9 citations g-index h-index papers 9 9 9 510 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	An αvâ€RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities. Angewandte Chemie - International Edition, 2018, 57, 3298-3321.	7.2	94
2	Translational pharmacology of an inhaled small molecule $\hat{l}\pm\hat{vl}^2$ 6 integrin inhibitor for idiopathic pulmonary fibrosis. Nature Communications, 2020, 11, 4659.	5.8	65
3	Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin $\hat{l}\pm v\hat{l}^26$ inhibitor, in healthy participants. European Journal of Clinical Pharmacology, 2018, 74, 701-709.	0.8	52
4	A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled $\hat{l}\pm v\hat{l}^26$ integrin inhibitor. Respiratory Research, 2020, 21, 75.	1.4	41
5	Discovery of (<i>S</i>)-3-(3-(3,5-Dimethyl-1 <i>H</i> -pyrazol-1-yl)phenyl)-4-((<i>R</i>)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridi Acid, a Nonpeptidic α _v β ₆ Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis. Iournal of Medicinal Chemistry. 2018. 61. 8417-8443.	n-2-yl)ethy	l)pyrrolidin-1
6	Pharmacological Characterization of the $\hat{l}\pm v\hat{l}^26$ Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2. Pharmacology, 2016, 97, 114-125.	0.9	26
7	Characterisation of a novel, high affinity and selective $\hat{l}\pm v\hat{l}^26$ integrin RGD-mimetic radioligand. Biochemical Pharmacology, 2016, 117, 88-96.	2.0	23
8	Downregulation of the $\hat{l}\pm v\hat{l}^26$ Integrin via RGD Engagement Is Affinity and Time Dependent. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 273-280.	1.3	3
9	Pharmacological characterisation of GSK3335103, an oral $\hat{l}\pm\nu\hat{l}^26$ integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease. European Journal of Pharmacology, 2021, 913, 174618.	1.7	3